Screener
Kymera Therapeutics KYMR Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2026 and December 31, 2025, 82,788,253 and 81,323,532 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 8 | 8 |
| Additional paid-in capital | 2,712,811 | 2,643,817 |
| Accumulated deficit | (1,196,406) | (1,065,961) |
| Accumulated other comprehensive (loss) income | (7,157) | 1,800 |
| Total stockholders’ equity | 1,509,256 | 1,579,664 |
| Total liabilities and stockholders’ equity | $1,645,444 | $1,742,812 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's total liabilities & equity?
- Kymera Therapeutics (KYMR) reported total liabilities & equity of $1.65B in Q2 2026.
- How has Kymera Therapeutics's total liabilities & equity changed year-over-year?
- Kymera Therapeutics's total liabilities & equity increased by 45.5% year-over-year, from $1.13B to $1.65B.
- What is the long-term trend for Kymera Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Kymera Therapeutics's total liabilities & equity has grown at a 29.0% compound annual growth rate (CAGR), from $487.18M to $1.74B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Kymera Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude